An integrative analysis combining single-cell transcriptomic data with Alzheimer's genetic risk loci identifies disease-associated genes expressed in specific immune cell populations, particularly brain-resident and peripheral immune lineages. The resulting gene set is then mapped against existing pharmacological compounds to generate drug repurposing candidates. The work positions immune regulation, rather than amyloid accumulation alone, as a tractable target in neurodegenerative disease.
Key Points
- Alzheimer's risk genes map disproportionately to specific immune cell types
- Single-cell resolution separates causal cell populations from bystander tissue
- Existing approved drugs matched to prioritized immune gene targets
Longevity Analysis
Cognitive decline is increasingly understood as a disorder of immune surveillance and clearance within neural tissue, not solely protein misfolding. Localizing genetic risk to defined immune populations clarifies which inflammatory processes are driving damage and which are responding to it — a distinction that determines whether an intervention helps or interferes. For practitioners, this strengthens the case for attending to chronic inflammatory load, glial clearance capacity, and the immune–neural interface decades before symptoms appear, while repurposing candidates offer a shorter translational path than novel compounds.
Original published by Nature - npj Aging, by Yifu Sun.